However, the enhanced migration of NCLX KO clones was abrogated when glycolysis was inhibited using 2-DG (Figure 7L–M; Figure 7—figure supplement 1J), suggesting that increased glycolysis is supporting migration of NCLX KO clones and that targeting this metabolic adaptation may be an avenue to block metastatic progression of CRC cells with low NCLX expression. Here, SLC8B1 is linked to colorectal carcinoma.